Dr. W. Wayne Lautt President and Chief Scientific Officer Wayne Lautt received his early training (BSc) in physiology from the U of Alberta, MSc and PhD in Pharmacology and Therapeutics from U of Manitoba, and held a post-doctoral position in Toxicology at the U of Montreal. He was the first Canadian Liver Foundation Scholar as a faculty member at the U of Saskatchewan where he rose to Professor prior to being recruited to U of Manitoba in 1984. He served as department head (1989-94). He received the prestigious Michael Smith award from the Canadian Institutes of Health Research, awards from the Canadian Physiological and Pharmacological Societies and from the Portuguese Diabetes Association. In 2000, based on his discovery of a new paradigm explaining insulin resistance in diabetes, he co-founded Diamedica Inc. Dr.Lautt has developed a therapeutic and preventative for insulin resistance, obesity, syndrome X, and Type II diabetes. He serves as consultant to, and is on the Scientific Advisory Board of DiaMedica Inc., is chairman of the Scientific Advisory Board for GLG Lifetech, and President and Chief Scientific Officer of SciMar Ltd.

Mick Lautt Chief Executive Officer A passionate entrepreneur and business consultant with 2 decades of experience, Mick has been involved in the start up and operation of 3 successful businesses and many exciting partnerships and projects. An expert in bringing people together to achieve results, Mick has been instrumental in helping to commercialize the patented invention offered here, and in bringing it to market. He currently serves as the Chief Executive Officer of SciMar Ltd.

SAMEC is a cocktail of three active ingredients that, when combined, show a synergistic action to prevent the onset of Pre Diabetic Insulin Resistance (PDIR), a condition associated with normal aging1 and from diets high in sugar2.

SAMEC:
S-adenosylmethionine + vitamin E + vitamin C

The individual components have all had dramatic medical claims made in hundreds of studies but none, on their own, protect against PDIR3. Their unique synergistic effect is the discovery that allows SAMEC to be patented.

SAMEC, as a daily supplement, should both prevent and halt the progression of metabolic diseases4 that are associated with diabetes and obesity. Studies in rats are dramatic and conclusive. The same mechanism is shown in humans.5,6

PDIR7   Pre Diabetic Insulin Resistance

• PDIR leads progressively to obesity and diabetes, with all the associated pathologies8 including dysfunctions in the kidneys eyes, nerves, blood vessels, and blood chemistries (cholesterol, triglyceride).
• PDIR can be caused by high levels of stress9, diets high in refined sugars10, diets high in excess fats11, normal aging12 , liver disease and other chronic inflammatory diseases13, fetal alcohol and other pre-birth insults.14
• PDIR can be treated once it has developed to an advanced disease state, including full stage type 2 diabetes.15 Current tests, however, only detect diabetes 10-15 years after the onset of PDIR.16
• PDIR can be prevented by exercise17 and by SAMEC.

Marketing Advantages

• The discovery of the mechanism of prediabetic insulin resistance that accounts for the progression to obesity, type 2 diabetes, and the associated pathologies, was made by Dr. Wayne Lautt. Lautt and colleagues have published approximately 40 scientific peer-reviewed articles in this research area. This discovery is so new that fewer than a half-dozen publications have arisen from groups not associated with Dr. Lautt’s research team.
• SAMEC has been shown to protect this newly discovered mechanism from deterioration caused by age and a high sucrose diet.
• To date, SAMEC has been used as a powerful research tool and has been pivotal in understanding the progression from PDIR to full stage diabetes and other major pathologies, including asthma and Alzheimer’s disease.
• The ingredients of SAMEC are synergistic. No other compound has been shown to be preventive for the development and progression of PDIR.
• Exercise is shown to produce metabolic benefits similar to SAMEC in prevention of PDIR.
• Those with lifestyles that do not include a regular exercise regimen and diets high in antioxidants, represent an exciting market potential for SAMEC.
• SciMar Ltd. has a patent pending for SAMEC.